We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

HOLOGIC Diagnostics

HOLOGIC Diagnostics offers innovative technology for cytology, molecular and perinatal testing that helps deliver ans... read more Featured Products: More products

Download Mobile App




Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

By LabMedica International staff writers
Posted on 20 Oct 2026

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment. More...

Reveal’s portfolio includes HER2DX, a test designed to support therapy optimization for patients with HER2-positive breast cancer.

Reveal Genomics develops diagnostic tools to help identify treatment options for patients with cancer, using laboratory techniques, computational applications, and machine learning to generate cancer research data. The acquisition remains subject to Spanish regulatory approval and other customary closing conditions.

Breast cancer treatment increasingly relies on diagnostic tools that characterize tumor biology and support individualized care, including for patients with HER2-positive or hormone receptor-positive early-stage disease. The planned acquisition of Reveal Genomics would broaden Hologic’s capabilities in this area, complementing its existing oncology diagnostics portfolio.

That portfolio includes Breast Cancer Index, a guideline-recognized genomic assay that helps inform decisions about extended endocrine therapy in women with hormone receptor-positive early-stage breast cancer. Adding Reveal’s tests is expected to expand the diagnostic options available to support breast cancer treatment decisions.

“Reveal Genomics’ portfolio is a strong strategic complement to our existing oncology offering within Diagnostic Solutions and would allow us to support even more women diagnosed with breast cancer. This acquisition demonstrates our commitment to innovation and meaningfully expands our ability to inform breast cancer treatment decisions, directly advancing our purpose to enable healthier lives everywhere, every day,” said Vitor Rocha, CEO, Diagnostic Solutions at Hologic.

“We founded Reveal Genomics to bring precision oncology closer to patients and improve breast cancer treatment decisions. Joining Hologic gives us the scale and capabilities to accelerate that mission and reach many more patients worldwide,” said Patricia Villagrasa-Gonzalez, CEO and co-founder of Reveal Genomics.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.